Choksi Laboratories Ltd Upgraded to Sell on Technical Improvements Despite Flat Financials

Quality Assessment Remains Weak Amid Flat Financials

Choksi Laboratories continues to grapple with weak long-term fundamentals. The company reported flat financial performance in Q3 FY25-26, with profit before tax excluding other income (PBT LESS OI) at a near break-even level of ₹-0.01 crore. Its average Return on Capital Employed (ROCE) stands at a modest 7.91%, indicating limited efficiency in generating returns from its capital base. Furthermore, net sales have grown at a subdued compound annual growth rate (CAGR) of 12.43% over the past five years, which is below expectations for a healthcare services firm aiming for robust expansion.

Debt servicing capacity remains a concern, with a high Debt to EBITDA ratio of 2.43 times, suggesting elevated leverage and potential strain on cash flows. These factors collectively sustain the company’s low-quality grade, reinforcing the cautious view on its fundamental strength.

Valuation Signals Mixed Signals but Remain Attractive

Despite fundamental weaknesses, Choksi Laboratories exhibits a valuation profile that could appeal to value-oriented investors. The company’s ROCE of 9.6% paired with an Enterprise Value to Capital Employed ratio of just 1.9 indicates a very attractive valuation relative to its capital base. The stock trades at a discount compared to its peers’ historical averages, suggesting potential upside if operational performance improves.

However, the price-to-earnings growth (PEG) ratio of 2 signals that the market is pricing in moderate growth expectations relative to earnings expansion. While profits have risen by 23.3% over the past year, the stock’s price return was negative at -17.40%, underperforming the broader BSE500 index, which declined by only -1.02% over the same period. This divergence highlights investor scepticism despite improving profitability.

Financial Trend: Flat Quarter and Underperformance

The company’s recent quarterly results have been uninspiring, with flat revenue and negligible profit growth. The Q3 FY25-26 results showed no significant improvement, reinforcing the view that Choksi Laboratories is struggling to gain momentum in a competitive healthcare services market.

Over the last year, the stock’s return of -17.40% starkly contrasts with the Sensex’s modest decline of -3.80%, underscoring the company’s underperformance. However, the longer-term picture is more favourable, with a remarkable 5-year return of 1187.71% and a 10-year return of 823.64%, far outpacing the Sensex’s 46.18% and 189.42% respectively. This suggests that while near-term challenges persist, the company has delivered substantial value over the long haul.

Technical Indicators Drive Upgrade to Sell

The primary catalyst for the recent upgrade from Strong Sell to Sell is a shift in technical indicators, which have improved from a bearish to a mildly bearish stance. Weekly MACD readings have turned mildly bullish, while monthly MACD remains mildly bearish, indicating a tentative positive momentum in the short term. Similarly, the KST (Know Sure Thing) indicator is mildly bullish on a weekly basis but mildly bearish monthly, reflecting mixed but improving technical signals.

Other technical metrics present a nuanced picture: the Relative Strength Index (RSI) shows no clear signal on both weekly and monthly charts, while Bollinger Bands remain mildly bearish weekly and bearish monthly. Daily moving averages continue to signal bearishness, and Dow Theory trends show no definitive direction. Overall, these mixed signals have led analysts to moderate their stance, recognising some technical improvement but maintaining caution.

Choksi Laboratories’ current price of ₹101.60 is closer to its 52-week low of ₹81.85 than its 52-week high of ₹236.70, reflecting the stock’s recent volatility and investor uncertainty. The day’s trading range between ₹98.70 and ₹103.60 further illustrates this cautious sentiment.

Shareholding and Market Capitalisation Context

Choksi Laboratories is classified as a micro-cap stock, which inherently carries higher volatility and risk compared to larger peers. The majority of its shares are held by non-institutional investors, which may contribute to less stable trading patterns and liquidity concerns. This ownership structure often results in heightened sensitivity to market sentiment and technical factors.

Investment Outlook and Analyst Conclusion

In summary, the upgrade from Strong Sell to Sell reflects a modest improvement in technical indicators, signalling that the stock may be stabilising after a prolonged bearish phase. However, fundamental weaknesses persist, including flat recent financial performance, weak long-term growth, and high leverage. Valuation metrics suggest the stock is attractively priced relative to capital employed, but the market’s cautious stance is evident in the stock’s underperformance versus benchmarks over the past year.

Investors should weigh the company’s long-term track record of strong returns against its current challenges and technical signals. The cautious upgrade indicates that while some headway has been made on the technical front, significant fundamental risks remain. As such, Choksi Laboratories may appeal to investors with a higher risk tolerance seeking value opportunities in the healthcare services micro-cap space, but it remains a speculative proposition.

Key Metrics at a Glance:

• Mojo Score: 31.0 (Upgraded from Strong Sell to Sell)
• Market Cap Grade: Micro-cap
• ROCE: 7.91% (average), 9.6% (valuation basis)
• Debt to EBITDA: 2.43 times
• Price Return 1 Year: -17.40%
• Profit Growth 1 Year: +23.3%
• Enterprise Value to Capital Employed: 1.9
• PEG Ratio: 2

Given these factors, the current Sell rating advises caution, with the potential for further reassessment should financial trends improve or technical indicators strengthen more decisively.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →